Physician profile
Samata Basani
NPI 1689929820
$417,493.45
in general payments reported to CMS, 2019-2025
62 companies · $125K in 2025
The $125K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,302 · 2020: $34K · 2021: $44K · 2022: $105K · 2023: $57K · 2024: $46K · 2025: $125K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $197K · Food and Beverage: $12K · Travel and Lodging: $12K · Consulting Fee: $3,775 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,500 · Education: $140 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $196,745.25 |
| Food and Beverage | $12,122.15 |
| Travel and Lodging | $11,776.94 |
| Consulting Fee | $3,775.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,500.00 |
| Education | $140.03 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $250,329.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $104,094.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $44,178.42 | 2019-2025 | Tepezza, Prolia, Evenity |
| Abbott Laboratories | $4,497.11 | 2021-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $3,476.26 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $1,118.53 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $905.65 | 2019-2025 | |
| Senseonics, Incorporated | $800.00 | 2025 | Eversense |
| Boehringer Ingelheim Pharmaceuticals, INC. | $723.40 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Mannkind Corporation | $701.72 | 2019-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $593.57 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $515.13 | 2019-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $443.69 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $430.35 | 2021-2025 | |
| Cequr Corporation | $385.66 | 2022-2025 | Cequr Simplicity |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $304.57 | 2020-2025 | Tymlos |
| Amneal Pharmaceuticals LLC | $271.14 | 2021-2025 | Unithroid |
| Abbvie INC. | $270.79 | 2019-2025 | Synthroid |
| Alexion Pharmaceuticals, INC. | $266.76 | 2019-2025 | Strensiq |
| Sequel Med Tech, LLC | $258.00 | 2024-2025 | Twiist |
| Horizon Therapeutics Plc | $223.91 | 2021-2023 | Tepezza |
| Zealand Pharma US, INC. | $196.66 | 2021-2022 | |
| Madrigal Pharmaceuticals | $182.21 | 2025 | Rezdiffra |
| Currax Pharmaceuticals LLC | $180.45 | 2019-2024 | Nexletol, Contrave |
| Intuity Medical INC | $174.86 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Medtronic, INC. | $161.57 | 2021-2024 | Minimed 780g, Intellis Adaptivestim |
| Amryt Pharma Holdings Ltd | $110.65 | 2021-2023 | Mycapssa |
| Tandem Diabetes Care, INC. | $109.32 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $108.03 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amphastar Pharmaceuticals, INC. | $106.89 | 2023-2025 | Baqsimi |
| Genzyme Corporation | $105.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $97.76 | 2019-2020 | |
| Pfizer INC. | $97.28 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.66 | 2019-2023 | Cycloset |
| Ibsa Pharma INC. | $83.74 | 2019-2025 | Tirosint, Licart, Tirosint |
| Merck Sharp & Dohme LLC | $76.27 | 2019-2021 | |
| Amarin Pharma, INC. | $75.73 | 2019-2022 | |
| Astellas Pharma US INC | $68.98 | 2024-2025 | Veozah |
| Recordati_rare_diseases_inc. | $62.51 | 2025 | Isturisa |
| Antares Pharma, INC. | $60.46 | 2019-2022 | |
| Ascensia Diabetes Care US INC. | $55.79 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $54.13 | 2025 | |
| Becton, Dickinson and Company | $49.84 | 2019-2021 | |
| Lifescan, INC. | $41.32 | 2020-2022 | |
| Clarus Therapeutics INC. | $40.46 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $38.68 | 2025 | Imcivree |
| Glaxosmithkline, LLC. | $25.67 | 2025 | Arexvy |
| Nestle Healthcare Nutrition INC. | $25.63 | 2021 | |
| Companion Medical, INC. | $21.82 | 2019 | |
| Rgh Enterprises LLC | $21.01 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $19.90 | 2021 | |
| Althera Pharmaceuticals LLC | $17.59 | 2021 | |
| Shire North American Group INC | $16.93 | 2019 | |
| Ascendis Pharma Endocrinology INC | $16.79 | 2025 | Yorvipath |
| Lexicon Pharmaceuticals, INC. | $16.38 | 2023 | Inpefa |
| Bigfoot Biomedical INC | $15.63 | 2022 | |
| Vivus LLC | $15.33 | 2021 | |
| Medtronic Minimed, INC. | $15.06 | 2020 | |
| Tolmar, INC. | $14.18 | 2025 | Jatenzo |
| Nalpropion Pharmaceuticals LLC | $13.20 | 2019 | |
| Vistapharm, INC. | $12.36 | 2021 | |
| Valeritas, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samata Basani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.